These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23454015)

  • 21. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
    Yun H; Heo HY; Kim HH; DooKim N; Seol W
    Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Synthesis of Pyrrolo[2,3-
    Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
    J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
    Ray S; Liu M
    Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
    Pedro L; Padrós J; Beaudet L; Schubert HD; Gillardon F; Dahan S
    Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
    Fuji RN; Flagella M; Baca M; Baptista MA; Brodbeck J; Chan BK; Fiske BK; Honigberg L; Jubb AM; Katavolos P; Lee DW; Lewin-Koh SC; Lin T; Liu X; Liu S; Lyssikatos JP; O'Mahony J; Reichelt M; Roose-Girma M; Sheng Z; Sherer T; Smith A; Solon M; Sweeney ZK; Tarrant J; Urkowitz A; Warming S; Yaylaoglu M; Zhang S; Zhu H; Estrada AA; Watts RJ
    Sci Transl Med; 2015 Feb; 7(273):273ra15. PubMed ID: 25653221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
    Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
    Estrada AA; Liu X; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chan BK; Chen H; Ding X; DiPasquale AG; Dominguez SL; Dotson J; Drummond J; Flagella M; Flynn S; Fuji R; Gill A; Gunzner-Toste J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Lyssikatos JP; Medhurst AD; Moffat JG; Mukund S; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Tran T; Trivedi N; Wang S; Zhang S; Zhang X; Zhao G; Zhu H; Sweeney ZK
    J Med Chem; 2012 Nov; 55(22):9416-33. PubMed ID: 22985112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
    Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
    Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
    Salado IG; Zaldivar-Diez J; Sebastián-Pérez V; Li L; Geiger L; González S; Campillo NE; Gil C; Morales AV; Perez DI; Martinez A
    Eur J Med Chem; 2017 Sep; 138():328-342. PubMed ID: 28688273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
    Anand VS; Reichling LJ; Lipinski K; Stochaj W; Duan W; Kelleher K; Pungaliya P; Brown EL; Reinhart PH; Somberg R; Hirst WD; Riddle SM; Braithwaite SP
    FEBS J; 2009 Jan; 276(2):466-78. PubMed ID: 19076219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
    Taymans JM
    Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
    Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
    J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
    Gilligan PJ
    Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
    Garofalo AW; Bright J; De Lombaert S; Toda AMA; Zobel K; Andreotti D; Beato C; Bernardi S; Budassi F; Caberlotto L; Gao P; Griffante C; Liu X; Mengatto L; Migliore M; Sabbatini FM; Sava A; Serra E; Vincetti P; Zhang M; Carlisle HJ
    J Med Chem; 2020 Dec; 63(23):14821-14839. PubMed ID: 33197196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.